Improving Tablet Quality with Compression to Equal Force Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Improving Tablet Quality with Compression to Equal Force Technology
Traditional tablet presses do not measure tablets' tensile strength, yet this characteristic strongly influences tablet quality. The author describes a compression technique that accounts for tensile strength and produces tablets with consistent weight and disintegration time.


Pharmaceutical Technology


The effect of equal porosity on tablet properties

The author performed an experiment using an ibuprofen 85 DC formulation with 0.5% magnesium stearate. The tabletting was done on the "MODUL P" tablet press (GEA Courtoy, Halle, Belgium). This press is equipped with the air compensator at precompression and main compression.

The advantage of equal porosity tableting is the reduction of variability in density, tensile strength, and disintegration.

Compression to EF. For the above formulation, a series of tablets was compressed at a constant force of 650 daN with a nominal tablet weight of 233 mg.

Tablets were compressed within 4% of their nominal weight. All tablets were compressed to the same peak compression force.

Compression to ET. The same series of tablets was compressed to ET. The distance between the two rollers remained constant throughout compression.

Results


Figure 5
Figures 5–8 show the analysis. The weight variation demonstrates an increase of force when the machine uses the ET mode and tablet weights increase.


Figure 6
The influence of tablet weight on density for ET and EF. Density increases as tablet weight increases. Density decreases when tablet weight decreases. The variability of the density during compression to EF is 1.1%. The variability of the density during compression to ET is 8%. Both tests used the same series of tablets within the same weight range.


Figure 7
Testing the tablets for tensile strength. The variability in tensile strength was more significant than that of density. Tablets compressed to EF showed as little as 1.2% variation. Tablets compressed to ET showed as much as 29.6% variation.


Figure 8
Testing the tablets for disintegration time. Disintegration time varied widely according to the compression technique. Tablets compressed to EF showed only 14.5% variability in disintegration time. Tablets compressed to ET, however, showed more than 105% variability in disintegration time.

Conclusion

The data were gathered under controlled conditions for ibuprofen 85 DC, and tablets were compressed within the US Pharmacopoeia's weight-variation limits.

Tablets compressed under equal force (EF) showed a much more consistent density, tensile strength, and disintegration rate than tablets compressed to equal thickness.

Different results might be expected from other drug formulations, but these data clearly indicate the advantage of a rotary press with EF capability.

Machines with both capabilities, therefore, give formulation and production departments great scope for improving tablet quality.

Johan Van Evelghem is a product and compression-technology manager at Courtoy, 9165 Rumsey Rd., Columbia, MD 21045, tel., 410.997.6692,

Reference

1. K.A. Khan and C.T. Rhodes, "Effect of Variation in Compaction Force on Properties of Six Direct Compression Tablet Formulations," J. Pharm. Sci. 65 (12), 1835–1837 (1976).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
43%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here